Device Week, 25 June 2021 – Major SPAC; Novel Heart Pump; And Breakthrough Device Designation
Executive Summary
In this edition of Device Week, Medtech Insight's UK-based reporter Barnaby Pickering provides an insight into Procyrion’s novel device for decongesting cardiorenal syndrome patients. US Commercial and R&D manager, Reed Miller, highlights details on Pear Therapeutics’ recent SPAC acquisition, and managing editor, Marion Webb, discusses two companies that received types of approval for novel devices.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.